Using broad-spectrum antibiotics for joint infections in orthopedic surgery
Interest in Probabilistic Antibiotic Therapy With Broad-spectrum Beta-lactams in Orthopedic Surgery
This study is testing whether using broad-spectrum antibiotics can help people with joint infections after orthopedic surgery when the exact bacteria causing the infection aren't known.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06191601 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the management of joint infections in orthopedic surgery by employing probabilistic antibiotic therapy with broad-spectrum beta-lactams. It involves a collaborative approach among rheumatologists, infectious disease specialists, and orthopedists to optimize patient care. The study aims to evaluate the effectiveness of initiating antibiotic treatment based on clinical and microbiological assessments, particularly in complex cases where the causative bacteria cannot be identified prior to treatment. Patients who underwent specific orthopedic procedures between January 1, 2021, and December 31, 2021, will be included in the analysis.
Who should consider this trial
Good fit: Ideal candidates are adults hospitalized in the ortho-traumatology department who underwent specific orthopedic surgeries during the study period.
Not a fit: Patients who have expressed opposition to the reuse of their data for research or those who underwent procedures not specified in the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve treatment outcomes for patients with joint infections by ensuring timely and appropriate antibiotic therapy.
How similar studies have performed: While the approach of using probabilistic antibiotic therapy is established, the specific application in this context is novel and may provide new insights into treatment efficacy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years old) * Hospitalized in the ortho-traumatology department * Operated between January 1, 2021 and December 31, 2021 * Probabilistic antibiotic therapy with cefepime or piperacillin-tazobactam combined with an anti-gram + antibiotic * Operated for: Change or washing of THA, TKA, PTE, ablation or resumption of osteosynthesis lower limbs and upper limbs and native osteitis * Absence of written opposition in the medical file of the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes. It is the responsibility of the investigator to verify the absence of opposition in the patient's medical file. Exclusion Criteria: * Patient having expressed his opposition to the reuse of his data for scientific research purposes. * Minor patient * Patient operated for: Amputation, plantar perforating pain, soft tissue infection * Patient for whom there is documentation leading to targeted probabilistic antibiotic therapy with beta lactams.
Where this trial is running
Strasbourg
- Service d'Orthopédie - Traumatologie Membre Supérieur - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Jean-Yves JENNY, MD, PhD
- Email: Jean-Yves.JENNY@chru-strasbourg.fr
- Phone: 33 3 68 76 51 76
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.